Related Experiment Videos
Angiotensin-converting enzyme inhibition, cell growth, and left ventricular hypertrophy in hypertension
1Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana.
Insights
Left ventricular hypertrophy (LVH) is a key risk for cardiovascular disease. Angiotensin-converting enzyme (ACE) inhibitors effectively reduce blood pressure and promote LVH regression, improving patient outcomes.
Area of Science:
- Cardiology
- Hypertension Research
- Pharmacology
Background:
- Left ventricular hypertrophy (LVH) is a significant risk marker for cardiovascular morbidity and mortality.
- LVH is a key component in the pathophysiology of primary hypertension, influenced by mechanical, neurohumoral, and genetic factors.
- The renin-angiotensin system plays a crucial role in LVH development through systemic blood pressure and direct myocardial effects.
Purpose of the Study:
- To evaluate the role of angiotensin-converting enzyme (ACE) inhibitors in managing left ventricular hypertrophy.
- To assess the impact of ACE inhibitor therapy on blood pressure, LVH regression, and cardiac function.
Main Methods:
- Review of existing literature on hypertension, LVH, and ACE inhibitor therapy.
- Analysis of studies investigating the effects of ACE inhibitors on blood pressure and cardiac structure/function.
Main Results:
- ACE inhibitors are effective in reducing blood pressure in patients with primary hypertension.
- ACE inhibitor therapy is associated with the regression of left ventricular hypertrophy.
- Regression of LVH with ACE inhibitors leads to restoration of normal diastolic and systolic left ventricular function.
Conclusions:
- Regression of left ventricular hypertrophy is linked to improved cardiovascular prognosis.
- ACE inhibitors are effective therapeutic agents when LVH regression is a treatment goal in hypertension.
Abstract:
Left ventricular hypertrophy is now recognized as an important risk marker in cardiovascular morbidity and mortality. Left ventricular hypertrophy is an integral component of the complex pathophysiology of primary hypertension and results from mechanical, neurohumoral, and genetic factors. The renin-angiotensin system is involved with the production of left ventricular hypertrophy, not only through the effects on systemic arterial blood pressure but also by both direct and indirect effects on myocardial cell growth. The angiotensin-converting enzyme (ACE) inhibitors are effective drugs for reducing blood pressure in primary hypertension. ACE inhibitor therapy is also associated with regression of left ventricular hypertrophy and restoration of normal diastolic and systolic left ventricular function. Regression of left ventricular hypertrophy is associated with improved prognosis. Thus, when left ventricular hypertrophy regression is a goal of antihypertensive treatment, the ACE inhibitors are effective drugs.